Oncolytic Measles Virus Delivery by Infected Cell Carriers - A Strategy To "By-Pass" the Pre-Existing Humoral Immune Response

被引：0
|
作者：
Iankov, Ianko D. [1 ]
Blechacz, Boris R. A. [1 ]
Griesmann, Guy E. [1 ]
Federspiel, Mark J. [1 ]
Russell, Stephen J. [1 ]
机构：
[1] Mayo Clin, Mol Med Program, Rochester, MN USA
来源：
MOLECULAR THERAPY | 2006年 / 13卷
关键词：
D O I：
10.1016/j.ymthe.2006.08.073
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
58
引用
收藏
页码：S24 / S25
页数：2
相关论文
共 18 条
  • [1] Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy
    Iankov, Ianko D.
    Blechacz, Boris
    Liu, Chunsheng
    Schmeckpeper, Jeffrey D.
    Tarara, James E.
    Federspiel, Mark J.
    Caplice, Noel
    Russell, Stephen J.
    [J]. MOLECULAR THERAPY, 2007, 15 (01) : 114 - 122
  • [2] Pre-Existing Antiviral State Can Impact Oncolytic Infection in Glioblastoma Patients Treated With Oncolytic Measles Virus
    Kurokawa, Cheyne
    Iankov, Ianko
    Aderca, Ileana
    Petell, Cory
    Middha, Sumit
    Giannini, Caterina
    Parney, Ian
    Galanis, Evanthia
    [J]. MOLECULAR THERAPY, 2014, 22 : S248 - S248
  • [3] Pre-Existing HSV-1 Immunity Enhances Anticancer Efficacy of a Novel Immune-Stimulating Oncolytic Virus
    Ding, Jun
    Murad, Yanal M.
    Sun, Yi
    Lee, I-Fang
    Samudio, Ismael
    Liu, Xiaohu
    Jia, William Wei-Guo
    Zhao, Ronghua
    [J]. VIRUSES-BASEL, 2022, 14 (11):
  • [4] Pre-existing HSV-1 Immunity enhances anti-cancer efficacy of a novel immune stimulating oncolytic virus-VG161.
    Ding, Jun
    Sun, Jason
    Murad, Yana
    Lee, Erica
    Samudio, Ismael
    Jia, William
    Zhao, Ronghua
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [5] Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice
    Croyle, Maria A.
    Patel, Ami
    Tran, Kaylie N.
    Gray, Michael
    Zhang, Yi
    Strong, James E.
    Feldmann, Heinz
    Kobinger, Gary P.
    [J]. PLOS ONE, 2008, 3 (10):
  • [6] Is pre-existing antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?
    Godet, Yann
    Dosset, Magalie
    Borg, Christophe
    Adotevi, Olivier
    [J]. ONCOIMMUNOLOGY, 2012, 1 (09): : 1617 - 1619
  • [7] Humoral response to mRNA-based COVID-19 vaccine in patients with de novo and pre-existing immune thrombocytopenia with exacerbation of thrombocytopenia after vaccination
    Mori, Akio
    Onozawa, Masahiro
    Kobayashi, Mirei
    Tsukamoto, Shihori
    Ishio, Takashi
    Yokoyama, Emi
    Izumiyama, Koh
    Saito, Makoto
    Muraki, Haruna
    Morioka, Masanobu
    Teshima, Takanori
    Kondo, Takeshi
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (04) : 627 - 630
  • [8] HUMORAL IMMUNE-RESPONSE TO T-CELL DEPENDENT AND INDEPENDENT ANTIGENS IN CATS INFECTED WITH FELINE IMMUNODEFICIENCY VIRUS
    TANIGUCHI, A
    ISHIDA, T
    WASHIZU, T
    TOMODA, I
    [J]. JOURNAL OF VETERINARY MEDICAL SCIENCE, 1991, 53 (02): : 333 - 335
  • [9] Pre-existing T cell immune response specific to computationally optimized broadly reactive hemagglutinin antigens (COBRA-HA) in influenza vaccinees
    Moraes, Vanessa S.
    Souquette, Aisha
    Ross, Ted M.
    [J]. JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [10] Study of the delivery of the gD gene of pseudorabies virus to one-day-old piglets by adenovirus or plasmid DNA as ways to by-pass the inhibition of immune response by colostral antibodies
    LePotier, MF
    Monteil, M
    Houdayer, C
    Eloit, M
    [J]. VETERINARY MICROBIOLOGY, 1997, 55 (1-4) : 75 - 80
12